Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eli Lilly and Company is conducting a Phase 2 clinical study titled ‘A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal.’ The study aims to evaluate the effectiveness of LY3457263 in reducing hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes who have not met their HbA1c targets despite being on stable doses of semaglutide or tirzepatide.
The study tests the drug LY3457263, administered subcutaneously, against a placebo. LY3457263 is intended to help patients achieve better control over their HbA1c levels.
This interventional study is randomized and follows a parallel assignment model. It employs double-blinding, meaning both participants and investigators are unaware of who receives the treatment or placebo. The primary goal is treatment-focused.
The study began on March 28, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 1, 2025, indicating ongoing recruitment.
The outcome of this study could significantly impact Eli Lilly’s stock performance and investor sentiment, especially if LY3457263 proves effective. Success could enhance Eli Lilly’s competitive position in the diabetes treatment market, potentially affecting competitors like Novo Nordisk.
The study is currently ongoing, with further details available on the ClinicalTrials portal.